Erratum: Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

This corrects the article on p. e30 in vol. 35, PMID: 38072400.

Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.

Cervical cancer continues to be a global threat affecting individuals in resource poor communities disproportionately. The treatment paradigm for this disease is ever evolving with recent innovations propelling oncologic outcomes to a new frontier offering survival benefits for patients struggling with locally advanced disease and metastatic/recurrent carcinoma. Immunologic checkpoint inhibitors and anti-body drug conjugates represent two novel drug classes that have demonstrable activity in this disease, particularly in the first-line and second-line treatment paradigm for recurrence.